Mirum Pharmaceuticals (MIRM) Financials

$109.16 +2.28 (+2.13%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$108.83 -0.33 (-0.30%)

As of 04:44 AM Eastern

Annual Income Statements for Mirum Pharmaceuticals

This table shows Mirum Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-53	-103	-84	-136	-163	-88	-23
Consolidated Net Income / (Loss)	-53	-103	-84	-136	-163	-88	-23
Net Income / (Loss) Continuing Operations	-53	-103	-84	-135	-163	-88	-23
Total Pre-Tax Income	-53	-103	-84	-142	-162	-87	-21
Total Operating Income	-55	-104	-173	-131	-109	-88	-22
Total Gross Profit	0.00	0.00	19	65	139	255	421
Total Revenue	0.00	0.00	19	77	186	337	521
Operating Revenue	-	0.00	19	77	186	337	521
Total Cost of Revenue	0.00	0.00	0.00	12	47	82	100
Operating Cost of Revenue	-	-	-	12	47	82	100
Total Operating Expenses	55	104	193	196	248	343	443
Selling, General & Admin Expense	12	23	59	89	146	202	257
Research & Development Expense	43	82	131	107	103	141	186
Total Other Income / (Expense), net	2.21	1.03	89	-11	-53	0.69	0.71
Interest Expense	0.00	0.34	18	16	64	14	14
Interest & Investment Income	2.23	1.56	0.37	3.86	14	14	13
Other Income / (Expense), net	-0.02	-0.19	107	0.91	-2.82	1.21	2.37
Income Tax Expense	0.02	0.01	0.04	-6.41	0.99	1.03	1.94
Basic Earnings per Share	($4.58)	($4.09)	($2.77)	($4.01)	($4.00)	($1.85)	($0.47)
Weighted Average Basic Shares Outstanding	11.49M	25.25M	30.32M	33.84M	40.89M	47.52M	50.20M
Diluted Earnings per Share	($4.58)	($4.09)	($2.77)	($4.02)	($4.00)	($1.85)	($0.47)
Weighted Average Diluted Shares Outstanding	11.49M	25.25M	30.32M	33.98M	40.89M	47.52M	50.20M
Weighted Average Basic & Diluted Shares Outstanding	11.49M	25.25M	30.32M	37.95M	47.00M	49.01M	60.34M

This table shows Mirum Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-24	-36	-25	-25	-14	-24	-15	-5.86	2.91	-5.73	-790
Consolidated Net Income / (Loss)	-24	-36	-25	-25	-14	-24	-15	-5.86	2.91	-5.73	-790
Net Income / (Loss) Continuing Operations	-24	-36	-25	-25	-14	-24	-15	-5.86	2.91	-5.73	-790
Total Pre-Tax Income	-23	-35	-25	-24	-14	-24	-14	-5.46	2.64	-4.96	-790
Total Operating Income	-25	-33	-26	-24	-13	-24	-15	-4.99	2.60	-4.57	-789
Total Gross Profit	37	45	51	58	70	77	89	104	107	121	131
Total Revenue	48	70	69	78	90	99	112	128	133	149	160
Operating Revenue	48	70	69	78	90	99	112	128	133	149	160
Total Cost of Revenue	10	25	18	20	21	23	23	23	26	28	29
Operating Cost of Revenue	10	25	18	20	21	23	23	23	26	28	29
Total Operating Expenses	63	77	78	82	82	101	104	109	105	125	921
Selling, General & Admin Expense	37	46	46	49	51	57	58	63	62	74	96
Research & Development Expense	26	31	32	33	32	44	46	46	43	51	824
Total Other Income / (Expense), net	1.81	-2.85	1.81	0.23	-1.20	-0.14	1.54	-0.47	0.04	-0.40	-0.22
Interest Expense	3.57	3.56	3.58	3.57	3.59	3.58	3.60	3.59	3.61	3.60	3.62
Interest & Investment Income	4.06	3.78	3.63	3.49	3.47	3.20	3.02	3.03	3.25	3.42	3.40
Other Income / (Expense), net	1.32	-3.06	1.76	0.31	-1.09	0.23	2.11	0.09	0.40	-0.22	0.00
Income Tax Expense	0.25	0.23	0.62	0.64	0.35	-0.58	1.03	0.40	-0.26	0.77	0.48
Basic Earnings per Share	($0.57)	($0.69)	($0.54)	($0.52)	($0.30)	($0.49)	($0.30)	($0.12)	$0.06	($0.11)	($13.43)
Weighted Average Basic Shares Outstanding	41.10M	40.89M	46.93M	47.24M	47.78M	47.52M	48.89M	49.73M	50.64M	50.20M	58.85M
Diluted Earnings per Share	($0.57)	($0.69)	($0.54)	($0.52)	($0.30)	($0.49)	($0.30)	($0.12)	$0.05	($0.10)	($13.43)
Weighted Average Diluted Shares Outstanding	41.10M	40.89M	46.93M	47.24M	47.78M	47.52M	48.89M	49.73M	56.99M	50.20M	58.85M
Weighted Average Basic & Diluted Shares Outstanding	46.61M	47.00M	47.13M	47.71M	48.00M	49.01M	49.53M	50.24M	51.39M	60.34M	60.98M

This table details how cash moves in and out of Mirum Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-40	130	-11	-3.34	158	-63	75
Net Cash From Operating Activities	-39	-89	-133	-120	-71	10	56
Net Cash From Continuing Operating Activities	-39	-87	-133	-120	-71	10	56
Net Income / (Loss) Continuing Operations	-53	-103	-84	-136	-163	-88	-23
Consolidated Net Income / (Loss)	-53	-103	-84	-136	-163	-88	-23
Depreciation Expense	0.14	0.31	0.60	3.24	11	24	24
Amortization Expense	-0.14	0.25	-0.14	0.00	1.12	1.66	1.74
Non-Cash Adjustments To Reconcile Net Income	5.99	13	-66	40	100	50	73
Changes in Operating Assets and Liabilities, net	7.21	2.43	17	-28	-19	23	-20
Net Cash From Investing Activities	-128	38	49	7.70	-107	-90	-24
Net Cash From Continuing Investing Activities	-128	38	49	7.70	-107	-90	-24
Purchase of Property, Plant & Equipment	-0.28	-0.23	-0.02	-0.28	-0.11	-0.99	-0.95
Acquisitions	-	-	-19	0.00	-233	-20	0.00
Purchase of Investments	-152	-75	-198	-132	-27	-89	-97
Sale and/or Maturity of Investments	25	113	158	140	153	20	74
Net Cash From Financing Activities	127	181	73	109	337	18	40
Net Cash From Continuing Financing Activities	127	181	73	109	337	18	40
Repurchase of Common Equity	0.00	-	0.00	0.00	-0.28	0.00	0.00
Issuance of Debt	-	-	0.00	0.00	305	0.00	0.00
Issuance of Common Equity	67	132	9.01	115	227	18	40
Other Financing Activities, net	0.00	50	64	-5.55	-196	0.00	0.00
Effect of Exchange Rate Changes	-	0.03	-0.00	0.01	-0.13	-1.30	3.22
Cash Interest Paid	-	-	0.00	0.00	6.82	13	13
Cash Income Taxes Paid	0.02	0.01	0.00	0.00	0.13	1.00	2.16

This table details how cash moves in and out of Mirum Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	5.83	-17	17	-69	-10	-0.47	-11	16	54	16	28
Net Cash From Operating Activities	-18	-17	15	-3.80	3.98	-5.07	-1.96	12	40	6.07	-229
Net Cash From Continuing Operating Activities	-18	-17	15	-3.80	3.98	-5.07	-1.96	12	40	6.07	-229
Net Income / (Loss) Continuing Operations	-24	-36	-25	-25	-14	-24	-15	-5.86	2.91	-5.73	-790
Consolidated Net Income / (Loss)	-24	-36	-25	-25	-14	-24	-15	-5.86	2.91	-5.73	-790
Depreciation Expense	2.66	5.49	5.66	5.85	6.06	6.06	6.05	6.06	6.06	6.07	6.87
Amortization Expense	0.41	0.40	0.41	0.41	0.42	0.42	0.43	0.43	0.44	0.44	0.45
Non-Cash Adjustments To Reconcile Net Income	7.94	21	10	15	8.41	14	18	18	18	19	453
Changes in Operating Assets and Liabilities, net	-5.64	-7.45	24	-0.79	3.33	-1.68	-11	-6.56	12	-14	101
Net Cash From Investing Activities	-183	-2.00	-0.01	-73	-18	0.64	-16	-6.60	-2.23	1.01	-12
Net Cash From Continuing Investing Activities	-183	-2.00	-0.01	-73	-18	0.64	-16	-6.60	-2.23	1.01	-12
Purchase of Property, Plant & Equipment	-	-	-0.01	-0.78	-0.18	-0.02	-0.04	-0.13	-0.19	-0.60	-0.66
Acquisitions	-213	-5.00	-	-10	-10	-	0.00	-	-	-	-10
Purchase of Investments	-	-	0.00	-62	-16	-11	-34	-32	-21	-12	-35
Sale and/or Maturity of Investments	30	3.00	0.00	-	7.75	12	17	25	19	13	34
Net Cash From Financing Activities	207	1.78	1.21	7.29	3.86	5.34	6.36	8.69	16	9.00	270
Net Cash From Continuing Financing Activities	207	1.78	1.21	7.29	3.86	5.34	6.36	8.69	16	9.00	270
Issuance of Common Equity	207	2.06	1.21	7.29	3.86	5.34	6.36	8.69	16	9.00	270
Effect of Exchange Rate Changes	-0.32	0.11	0.11	-0.12	0.09	-1.38	1.06	2.23	0.35	-0.41	-1.27
Cash Income Taxes Paid	-	0.13	0.14	0.20	0.43	0.23	0.16	1.49	0.50	0.01	0.22

This table presents Mirum Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	52	147	241	295	353	647	671	843
Total Current Assets	52	119	236	167	190	388	393	550
Cash & Equivalents	52	12	142	31	28	286	223	297
Restricted Cash	-	-	-	-	-	0.00	0.43	1.48
Short-Term Investments	0.00	105	90	125	124	0.00	58	87
Accounts Receivable	-	-	0.00	3.27	24	68	78	123
Inventories, net	-	-	0.00	1.51	5.57	22	22	25
Prepaid Expenses	0.01	2.70	4.53	5.27	8.95	11	12	18
Plant, Property, & Equipment, net	0.00	1.37	1.29	0.98	0.91	0.71	1.14	1.86
Total Noncurrent Assets	0.00	26	3.22	127	162	258	276	290
Long-Term Investments	0.00	23	0.00	4.98	-	0.00	13	8.11
Intangible Assets	-	-	0.00	19	59	253	250	261
Other Noncurrent Operating Assets	0.00	2.69	3.22	103	103	5.45	14	21
Total Liabilities & Shareholders' Equity	52	147	241	295	353	647	671	843
Total Liabilities	2.45	16	69	174	211	398	445	528
Total Current Liabilities	2.45	13	18	43	65	87	127	206
Accounts Payable	0.27	3.35	3.15	9.17	8.69	7.42	15	9.61
Accrued Expenses	2.18	9.33	13	31	54	79	112	196
Other Current Liabilities	0.00	0.40	1.90	2.71	2.02	1.10	-	0.00
Total Noncurrent Liabilities	0.00	3.29	50	132	146	311	319	322
Long-Term Debt	-	-	-	-	0.00	306	308	310
Other Noncurrent Operating Liabilities	0.00	3.29	50	132	146	4.47	10	13
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-17	130	172	120	142	249	226	315
Total Preferred & Common Equity	-17	130	172	120	142	249	226	315
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-17	130	172	120	142	249	226	315
Common Stock	0.04	200	345	377	535	803	870	982
Retained Earnings	-17	-70	-173	-257	-393	-556	-644	-668
Accumulated Other Comprehensive Income / (Loss)	0.00	0.13	0.08	-0.04	-0.22	1.64	-0.37	0.35

This table presents Mirum Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	364	334	444	651	652	661	668	690	726	785	891
Total Current Assets	216	172	384	389	389	368	387	411	453	531	569
Cash & Equivalents	36	49	297	303	303	233	223	212	228	282	325
Restricted Cash	-	-	-	0.00	-	0.25	0.43	0.43	0.48	0.48	1.73
Short-Term Investments	150	83	33	2.97	-	45	61	66	76	94	61
Accounts Receivable	16	25	35	48	55	60	69	96	107	107	133
Inventories, net	6.94	6.61	8.51	22	22	20	22	22	23	24	26
Prepaid Expenses	6.93	8.99	9.73	12	10	8.59	12	15	19	24	25
Plant, Property, & Equipment, net	0.80	0.88	0.87	0.79	0.50	1.10	1.21	1.11	1.18	1.28	2.41
Total Noncurrent Assets	148	160	59	261	262	292	280	278	271	253	317
Long-Term Investments	0.00	-	-	-	-	17	9.32	21	17	2.47	34
Intangible Assets	45	58	56	258	257	262	256	244	238	232	254
Other Noncurrent Operating Assets	103	103	2.77	2.94	4.55	13	15	13	16	18	29
Total Liabilities & Shareholders' Equity	364	334	444	651	652	661	668	690	726	785	891
Total Liabilities	195	192	365	382	417	432	436	457	471	493	648
Total Current Liabilities	51	49	58	75	106	112	116	128	145	160	273
Accounts Payable	11	6.44	14	7.37	16	9.84	9.55	12	18	12	59
Accrued Expenses	38	40	43	66	90	101	105	116	127	148	188
Other Current Liabilities	2.54	2.00	1.06	1.08	0.36	1.07	1.51	-	-	-	26
Total Noncurrent Liabilities	144	144	307	307	311	319	320	329	326	333	376
Long-Term Debt	-	-	306	306	307	307	308	309	309	309	310
Other Noncurrent Operating Liabilities	144	144	1.16	0.88	4.62	12	12	21	17	23	65
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	169	141	79	269	235	229	232	233	255	292	242
Total Preferred & Common Equity	169	141	79	269	235	229	232	233	255	292	242
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	169	141	79	269	235	229	232	233	255	292	242
Common Stock	526	564	576	791	816	836	851	892	920	954	1,700
Retained Earnings	-356	-423	-497	-521	-582	-606	-620	-659	-665	-662	-1,458
Accumulated Other Comprehensive Income / (Loss)	-0.41	0.14	0.08	-1.46	-0.01	-0.48	0.92	-0.26	0.35	0.04	-0.03

This table displays calculated financial ratios and metrics derived from Mirum Pharmaceuticals' official financial filings.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	302.66%	141.85%	80.76%	54.74%
EBITDA Growth	0.00%	-89.78%	36.24%	-91.76%	21.28%	38.92%	110.18%
EBIT Growth	0.00%	-90.80%	36.14%	-95.29%	14.07%	22.85%	77.12%
NOPAT Growth	0.00%	-90.52%	-66.27%	24.33%	16.82%	19.74%	74.73%
Net Income Growth	0.00%	-96.51%	18.67%	-61.53%	-20.45%	46.18%	73.43%
EPS Growth	0.00%	10.70%	32.27%	-45.13%	0.50%	53.75%	74.59%
Operating Cash Flow Growth	0.00%	-126.30%	-49.04%	9.51%	40.95%	114.55%	440.70%
Free Cash Flow Firm Growth	0.00%	0.00%	-510.88%	11.67%	-187.37%	90.70%	79.97%
Invested Capital Growth	0.00%	-521.94%	30.83%	76.56%	2,875.92%	-10.53%	-3.69%
Revenue Q/Q Growth	0.00%	0.00%	19.61%	47.36%	28.78%	9.73%	10.50%
EBITDA Q/Q Growth	0.00%	-21.35%	59.72%	-282.02%	3.97%	18.60%	147.74%
EBIT Q/Q Growth	0.00%	-21.31%	59.56%	-276.47%	-1.42%	11.89%	49.28%
NOPAT Q/Q Growth	0.00%	-21.27%	-5.23%	8.00%	1.42%	8.71%	47.03%
Net Income Q/Q Growth	0.00%	-22.91%	53.01%	-225.43%	0.47%	11.89%	43.60%
EPS Q/Q Growth	0.00%	-417.05%	54.74%	-258.93%	6.98%	9.76%	45.35%
Operating Cash Flow Q/Q Growth	0.00%	-33.96%	2.30%	-0.94%	19.92%	942.86%	24.92%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	-806.47%	46.87%	2.15%	24.28%	0.88%
Invested Capital Q/Q Growth	0.00%	-342.60%	72.21%	39.68%	-0.11%	-2.05%	3.88%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	100.00%	83.94%	74.76%	75.77%	80.77%
EBITDA Margin	0.00%	0.00%	-346.27%	-164.90%	-53.67%	-18.14%	1.19%
Operating Margin	0.00%	0.00%	-906.12%	-170.28%	-58.57%	-26.00%	-4.25%
EBIT Margin	0.00%	0.00%	-348.66%	-169.10%	-60.08%	-25.64%	-3.79%
Profit (Net Income) Margin	0.00%	0.00%	-438.85%	-176.05%	-87.68%	-26.10%	-4.48%
Tax Burden Percent	100.04%	100.01%	100.04%	95.49%	100.61%	101.19%	109.04%
Interest Burden Percent	95.92%	98.83%	125.81%	109.02%	145.05%	100.60%	108.41%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	-58.98%	-24.09%	-6.57%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	73.22%	-176.58%	16.47%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	-24.67%	-13.00%	-2.08%
Return on Equity (ROE)	-58.43%	-68.29%	-57.47%	-103.46%	-83.65%	-37.08%	-8.65%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	-132.03%	-12.97%	-2.80%
Operating Return on Assets (OROA)	0.00%	0.00%	-24.92%	-40.25%	-22.41%	-13.12%	-2.61%
Return on Assets (ROA)	0.00%	0.00%	-31.37%	-41.90%	-32.70%	-13.35%	-3.09%
Return on Common Equity (ROCE)	-36.72%	-68.29%	-57.47%	-103.46%	-83.65%	-37.08%	-8.65%
Return on Equity Simple (ROE_SIMPLE)	-40.32%	-60.01%	-69.87%	-95.51%	-65.72%	-38.97%	0.00%
Net Operating Profit after Tax (NOPAT)	-38	-73	-121	-92	-76	-61	-15
NOPAT Margin	0.00%	0.00%	-634.28%	-119.19%	-41.00%	-18.20%	-2.97%
Net Nonoperating Expense Percent (NNEP)	-10.17%	-16.28%	19.02%	-27.97%	-132.21%	152.49%	-23.04%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-64.67%	-13.76%	-11.49%	-2.48%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	16.06%	25.24%	24.23%	19.23%
SG&A Expenses to Revenue	0.00%	0.00%	309.44%	115.58%	78.27%	60.03%	49.30%
R&D to Revenue	0.00%	0.00%	686.74%	138.64%	55.06%	41.74%	35.71%
Operating Expenses to Revenue	0.00%	0.00%	1,006.12%	254.22%	133.33%	101.77%	85.02%
Earnings before Interest and Taxes (EBIT)	-55	-104	-67	-130	-112	-86	-20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-55	-104	-66	-127	-100	-61	6.22
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.32	2.61	4.07	5.06	5.53	8.80	12.90
Price to Tangible Book Value (P/TBV)	4.32	2.61	4.82	8.65	0.00	0.00	75.50
Price to Revenue (P/Rev)	0.00	0.00	25.53	9.33	7.38	5.89	7.79
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	5.19	8.32	17.17
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	17.09	7.36	7.49	5.94	7.63
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	639.51
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	193.69	71.23
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	1.23	1.37	0.98
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	1.23	1.37	0.98
Financial Leverage	-1.07	-1.23	-1.35	-1.19	-0.34	0.07	-0.13
Leverage Ratio	1.10	1.28	1.83	2.47	2.56	2.78	2.80
Compound Leverage Factor	1.06	1.27	2.30	2.69	3.71	2.79	3.04
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	55.20%	57.72%	49.61%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	55.20%	57.72%	49.61%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	44.80%	42.28%	50.39%
Debt to EBITDA	0.00	0.00	0.00	0.00	-3.06	-5.04	49.82
Net Debt to EBITDA	0.00	0.00	0.00	0.00	-0.20	-0.24	-13.37
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	-3.06	-5.04	49.82
Debt to NOPAT	0.00	0.00	0.00	0.00	-4.01	-5.02	-19.99
Net Debt to NOPAT	0.00	0.00	0.00	0.00	-0.26	-0.24	5.36
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	-4.01	-5.02	-19.99
Altman Z-Score	19.64	2.57	0.28	-0.09	1.14	1.88	4.53
Noncontrolling Interest Sharing Ratio	37.16%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	9.13	12.80	3.91	2.94	4.45	3.10	2.67
Quick Ratio	8.92	12.56	3.75	2.71	4.07	2.83	2.46
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-23	-140	-123	-355	-33	-6.61
Operating Cash Flow to CapEx	-14,007.83%	-39,588.89%	-553,158.33%	-43,214.39%	-65,086.24%	1,039.78%	5,851.89%
Free Cash Flow to Firm to Interest Expense	0.00	-68.31	-7.95	-7.73	-5.53	-2.31	-0.46
Operating Cash Flow to Interest Expense	0.00	-265.90	-7.55	-7.52	-1.11	0.72	3.88
Operating Cash Flow Less CapEx to Interest Expense	0.00	-266.57	-7.55	-7.54	-1.11	0.65	3.81
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.07	0.24	0.37	0.51	0.69
Accounts Receivable Turnover	0.00	0.00	0.00	5.65	4.05	4.61	5.17
Inventory Turnover	0.00	0.00	0.00	3.50	3.37	3.65	4.24
Fixed Asset Turnover	0.00	0.00	16.83	81.33	230.09	365.19	347.43
Accounts Payable Turnover	0.00	0.00	0.00	1.39	5.84	7.41	8.27
Days Sales Outstanding (DSO)	0.00	0.00	0.00	64.56	90.05	79.23	70.58
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	104.39	108.16	99.95	86.10
Days Payable Outstanding (DPO)	0.00	0.00	0.00	263.35	62.49	49.25	44.12
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	-94.40	135.72	129.93	112.56
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	-9.60	-60	-41	-9.68	269	240	232
Invested Capital Turnover	0.00	0.00	-0.38	-3.02	1.44	1.32	2.21
Increase / (Decrease) in Invested Capital	0.00	-50	18	32	278	-28	-8.88
Enterprise Value (EV)	424	217	327	567	1,396	2,000	3,976
Market Capitalization	564	449	489	719	1,376	1,985	4,060
Book Value per Share	$5.67	$6.69	$3.92	$3.85	$5.33	$4.70	$6.12
Tangible Book Value per Share	$5.67	$6.69	$3.31	$2.25	($0.09)	($0.50)	$1.05
Total Capital	130	172	120	142	555	534	624
Total Debt	0.00	0.00	0.00	0.00	306	308	310
Total Long-Term Debt	0.00	0.00	0.00	0.00	306	308	310
Net Debt	-140	-232	-162	-152	20	15	-83
Capital Expenditures (CapEx)	0.28	0.23	0.02	0.28	0.11	0.99	0.95
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-10	-14	-33	-26	14	-15	-41
Debt-free Net Working Capital (DFNWC)	106	218	124	125	300	266	344
Net Working Capital (NWC)	106	218	124	125	300	266	344
Net Nonoperating Expense (NNE)	14	30	-37	44	87	27	7.87
Net Nonoperating Obligations (NNO)	-140	-232	-162	-152	20	15	-83
Total Depreciation and Amortization (D&A)	-0.00	0.55	0.46	3.24	12	25	26
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	-170.05%	-34.03%	7.59%	-4.31%	-7.85%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	647.90%	162.85%	161.22%	79.03%	65.97%
Net Working Capital to Revenue	0.00%	0.00%	647.90%	162.85%	161.22%	79.03%	65.97%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($4.58)	($4.09)	($2.77)	($4.01)	($4.00)	($1.85)	($0.47)
Adjusted Weighted Average Basic Shares Outstanding	25.39M	30.42M	31.73M	33.84M	40.89M	47.52M	50.20M
Adjusted Diluted Earnings per Share	($4.58)	($4.09)	($2.77)	($4.02)	($4.00)	($1.85)	($0.47)
Adjusted Weighted Average Diluted Shares Outstanding	25.39M	30.42M	31.73M	33.98M	40.89M	47.52M	50.20M
Adjusted Basic & Diluted Earnings per Share	($4.58)	($4.09)	($2.77)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	11.49M	25.25M	30.32M	37.95M	47.00M	49.01M	60.34M
Normalized Net Operating Profit after Tax (NOPAT)	-38	-73	-121	-92	-76	-61	-15
Normalized NOPAT Margin	0.00%	0.00%	-634.28%	-119.19%	-41.00%	-18.20%	-2.97%
Pre Tax Income Margin	0.00%	0.00%	-438.66%	-184.36%	-87.15%	-25.80%	-4.11%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-311.90	-3.79	-8.16	-1.74	-6.04	-1.37
NOPAT to Interest Expense	0.00	-217.93	-6.90	-5.75	-1.19	-4.29	-1.08
EBIT Less CapEx to Interest Expense	0.00	-312.58	-3.79	-8.17	-1.75	-6.11	-1.44
NOPAT Less CapEx to Interest Expense	0.00	-218.60	-6.90	-5.77	-1.19	-4.35	-1.14
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	-0.17%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Mirum Pharmaceuticals' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	60,341,617.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	60,341,617.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-13.09
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	154.13%	149.24%	119.07%	107.68%	89.37%	42.93%	61.20%	64.09%	47.17%	49.81%	43.28%
EBITDA Growth	36.26%	8.60%	30.01%	22.90%	64.86%	41.12%	64.63%	108.95%	230.32%	109.85%	-11,768.54%
EBIT Growth	27.96%	-3.50%	11.62%	2.55%	42.20%	32.70%	47.09%	79.50%	121.77%	80.06%	-5,937.97%
NOPAT Growth	23.52%	4.61%	2.50%	0.17%	49.56%	25.67%	42.64%	79.41%	132.22%	81.15%	-5,099.66%
Net Income Growth	33.94%	2.12%	16.10%	66.72%	39.65%	33.28%	41.94%	76.21%	120.41%	75.91%	-5,283.63%
EPS Growth	44.12%	30.30%	32.50%	73.20%	47.37%	28.99%	44.44%	76.92%	116.67%	79.59%	-4,376.67%
Operating Cash Flow Growth	29.99%	51.51%	181.03%	78.06%	121.86%	69.50%	-112.89%	416.59%	896.01%	219.71%	-11,565.63%
Free Cash Flow Firm Growth	-94.55%	-442.39%	-320.01%	-137.63%	104.85%	103.77%	94.04%	97.59%	73.15%	-49.92%	-2,877.40%
Invested Capital Growth	1,776.47%	2,875.92%	2,528.57%	343.24%	-8.76%	-10.53%	1.74%	0.59%	-9.20%	-3.69%	-46.28%
Revenue Q/Q Growth	27.28%	45.74%	-0.48%	12.50%	16.05%	10.00%	12.24%	14.52%	4.09%	11.97%	7.35%
EBITDA Q/Q Growth	9.39%	-43.37%	37.44%	5.23%	58.71%	-140.25%	62.38%	123.98%	501.46%	-81.85%	-45,441.28%
EBIT Q/Q Growth	2.94%	-49.61%	30.68%	3.20%	42.43%	-74.21%	45.50%	62.50%	161.15%	-259.61%	-16,398.75%
NOPAT Q/Q Growth	-3.60%	-29.57%	18.77%	8.45%	47.66%	-90.97%	37.32%	67.14%	181.92%	-211.74%	-17,186.29%
Net Income Q/Q Growth	68.14%	-51.17%	29.11%	2.54%	42.22%	-67.12%	38.31%	60.07%	149.56%	-297.25%	-13,689.79%
EPS Q/Q Growth	70.62%	-21.05%	21.74%	3.70%	42.31%	-63.33%	38.78%	60.00%	141.67%	-300.00%	-13,330.00%
Operating Cash Flow Q/Q Growth	-5.14%	8.80%	191.54%	-125.00%	204.76%	-227.21%	61.31%	713.97%	229.58%	-84.71%	-3,870.61%
Free Cash Flow Firm Q/Q Growth	-253.97%	0.49%	17.66%	18.07%	107.23%	-22.74%	-230.24%	66.83%	618.71%	-77.65%	-7,842.94%
Invested Capital Q/Q Growth	395.83%	-0.11%	-11.23%	0.81%	2.06%	-2.05%	0.96%	-0.33%	-7.87%	3.88%	-43.69%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	78.57%	64.03%	74.24%	74.03%	76.98%	77.09%	79.37%	81.67%	80.80%	81.02%	81.98%
EBITDA Margin	-43.48%	-42.78%	-26.92%	-22.68%	-8.07%	-17.62%	-5.91%	1.24%	7.14%	1.16%	-489.20%
Operating Margin	-52.69%	-46.85%	-38.24%	-31.12%	-14.03%	-24.36%	-13.61%	-3.90%	1.96%	-3.07%	-493.78%
EBIT Margin	-49.92%	-51.25%	-35.70%	-30.72%	-15.24%	-24.13%	-11.72%	-3.84%	2.25%	-3.21%	-493.78%
Profit (Net Income) Margin	-49.42%	-51.27%	-36.52%	-31.64%	-15.75%	-23.93%	-13.15%	-4.59%	2.18%	-3.85%	-494.21%
Tax Burden Percent	101.07%	100.64%	102.53%	102.65%	102.50%	97.64%	107.54%	107.36%	109.91%	115.45%	100.06%
Interest Burden Percent	97.96%	99.41%	99.77%	100.35%	100.85%	101.56%	104.38%	111.34%	88.16%	103.72%	100.03%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-9.91%	0.00%	0.00%
Return on Invested Capital (ROIC)	-42.20%	-47.18%	-48.41%	-39.07%	-11.72%	-22.57%	-15.01%	-4.86%	4.33%	-4.74%	-1,055.24%
ROIC Less NNEP Spread (ROIC-NNEP)	-35.74%	-27.66%	-37.87%	80.89%	-91.27%	-61.72%	-75.04%	279.67%	4.18%	2.68%	-592.20%
Return on Net Nonoperating Assets (RNNOA)	15.11%	9.32%	12.91%	-3.37%	-2.45%	-4.54%	-2.16%	-0.96%	-0.44%	-0.34%	127.71%
Return on Equity (ROE)	-27.09%	-37.86%	-35.51%	-42.43%	-14.18%	-27.11%	-17.17%	-5.82%	3.89%	-5.08%	-927.53%
Cash Return on Invested Capital (CROIC)	-134.77%	-132.03%	-246.66%	-177.86%	-16.95%	-12.97%	-23.93%	-17.15%	-2.85%	-2.80%	-238.58%
Operating Return on Assets (OROA)	-14.24%	-19.11%	-16.23%	-14.71%	-7.10%	-12.34%	-6.62%	-2.38%	1.46%	-2.21%	-355.77%
Return on Assets (ROA)	-14.09%	-19.12%	-16.60%	-15.15%	-7.34%	-12.24%	-7.43%	-2.84%	1.42%	-2.65%	-356.08%
Return on Common Equity (ROCE)	-27.09%	-37.86%	-35.51%	-42.43%	-14.18%	-27.11%	-17.17%	-5.82%	3.89%	-5.08%	-927.53%
Return on Equity Simple (ROE_SIMPLE)	-61.02%	0.00%	-67.59%	-47.67%	-43.02%	0.00%	-33.16%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-18	-23	-19	-17	-8.88	-17	-11	-3.49	2.86	-3.20	-553
NOPAT Margin	-36.89%	-32.79%	-26.77%	-21.78%	-9.82%	-17.06%	-9.52%	-2.73%	2.15%	-2.15%	-345.65%
Net Nonoperating Expense Percent (NNEP)	-6.46%	-19.52%	-10.54%	-119.96%	79.55%	39.15%	60.03%	-284.53%	0.16%	-7.42%	-463.04%
Return On Investment Capital (ROIC_SIMPLE)	-	-4.11%	-	-	-	-3.18%	-1.96%	-0.62%	0.48%	-0.51%	-99.98%
Cost of Revenue to Revenue	21.43%	35.97%	25.76%	25.97%	23.02%	22.91%	20.63%	18.33%	19.20%	18.98%	18.02%
SG&A Expenses to Revenue	76.54%	66.40%	65.93%	63.19%	55.93%	57.17%	51.71%	49.53%	46.55%	49.77%	60.25%
R&D to Revenue	54.72%	44.48%	46.55%	41.95%	35.09%	44.29%	41.26%	36.05%	32.30%	34.32%	515.51%
Operating Expenses to Revenue	131.26%	110.88%	112.48%	105.14%	91.01%	101.45%	92.98%	85.58%	78.84%	84.09%	575.76%
Earnings before Interest and Taxes (EBIT)	-24	-36	-25	-24	-14	-24	-13	-4.90	3.00	-4.79	-789
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-21	-30	-19	-18	-7.29	-18	-6.59	1.58	9.50	1.73	-782
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.50	5.53	5.03	7.04	8.02	8.80	9.47	9.88	12.61	12.90	22.99
Price to Tangible Book Value (P/TBV)	112.65	0.00	0.00	0.00	0.00	0.00	0.00	145.81	61.23	75.50	0.00
Price to Revenue (P/Rev)	8.36	7.38	5.27	6.10	6.06	5.89	5.82	5.87	7.81	7.79	9.79
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	4.50	5.19	4.97	6.75	7.63	8.32	9.14	10.36	16.21	17.17	41.89
Enterprise Value to Revenue (EV/Rev)	8.36	7.49	5.29	6.14	6.10	5.94	5.85	5.84	7.66	7.63	9.59
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	639.51	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	193.69	0.00	278.78	80.86	71.23	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.14	1.23	1.31	1.34	1.33	1.37	1.32	1.21	1.06	0.98	1.28
Long-Term Debt to Equity	1.14	1.23	1.31	1.34	1.33	1.37	1.32	1.21	1.06	0.98	1.28
Financial Leverage	-0.42	-0.34	-0.34	-0.04	0.03	0.07	0.03	0.00	-0.11	-0.13	-0.22
Leverage Ratio	2.32	2.56	2.62	3.59	2.63	2.78	2.87	2.86	2.77	2.80	3.32
Compound Leverage Factor	2.27	2.54	2.62	3.60	2.65	2.82	2.99	3.19	2.44	2.91	3.32
Debt to Total Capital	53.21%	55.20%	56.67%	57.30%	57.01%	57.72%	56.95%	54.77%	51.44%	49.61%	56.13%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	53.21%	55.20%	56.67%	57.30%	57.01%	57.72%	56.95%	54.77%	51.44%	49.61%	56.13%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	46.79%	44.80%	43.33%	42.70%	42.99%	42.28%	43.05%	45.23%	48.56%	50.39%	43.87%
Debt to EBITDA	-2.94	-3.06	-3.27	-3.47	-4.10	-5.04	-6.29	-10.36	-23.75	49.82	-0.40
Net Debt to EBITDA	0.00	-0.20	-0.04	-0.13	-0.18	-0.24	-0.19	0.44	5.31	-13.37	0.15
Long-Term Debt to EBITDA	-2.94	-3.06	-3.27	-3.47	-4.10	-5.04	-6.29	-10.36	-23.75	49.82	-0.40
Debt to NOPAT	-3.95	-4.01	-4.04	-4.05	-4.58	-5.02	-5.77	-7.73	-10.58	-19.99	-0.56
Net Debt to NOPAT	0.00	-0.26	-0.05	-0.15	-0.20	-0.24	-0.18	0.33	2.36	5.36	0.20
Long-Term Debt to NOPAT	-3.95	-4.01	-4.04	-4.05	-4.58	-5.02	-5.77	-7.73	-10.58	-19.99	-0.56
Altman Z-Score	1.46	1.53	1.19	1.70	2.14	2.19	2.54	3.01	4.48	4.59	0.98
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.20	4.45	3.68	3.28	3.34	3.10	3.22	3.13	3.31	2.67	2.09
Quick Ratio	4.74	4.07	3.38	3.02	3.05	2.83	2.93	2.84	3.01	2.46	1.90
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-303	-301	-248	-203	15	11	-15	-4.91	25	5.69	-440
Operating Cash Flow to CapEx	0.00%	0.00%	117,015.38%	-488.19%	2,201.11%	-25,340.00%	-4,782.93%	9,555.56%	21,219.79%	1,011.17%	-34,452.26%
Free Cash Flow to Firm to Interest Expense	-84.70	-84.55	-69.34	-56.94	4.10	3.17	-4.11	-1.37	7.06	1.58	-121.76
Operating Cash Flow to Interest Expense	-5.10	-4.66	4.25	-1.07	1.11	-1.42	-0.55	3.35	11.00	1.69	-63.26
Operating Cash Flow Less CapEx to Interest Expense	-5.10	-4.66	4.25	-1.28	1.06	-1.42	-0.56	3.32	10.95	1.52	-63.45
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.29	0.37	0.45	0.48	0.47	0.51	0.57	0.62	0.65	0.69	0.72
Accounts Receivable Turnover	4.51	4.05	5.62	5.52	5.28	4.61	5.03	5.13	5.37	5.17	4.98
Inventory Turnover	1.51	3.37	0.91	1.81	1.68	3.65	3.94	4.15	4.15	4.24	4.42
Fixed Asset Turnover	182.97	230.09	325.11	268.81	307.18	365.19	471.41	376.79	379.10	347.43	323.64
Accounts Payable Turnover	2.46	5.84	1.15	2.16	4.36	7.41	6.29	6.55	8.73	8.27	2.99
Days Sales Outstanding (DSO)	80.92	90.05	64.90	66.10	69.17	79.23	72.59	71.13	67.95	70.58	73.36
Days Inventory Outstanding (DIO)	241.96	108.16	400.74	201.13	217.17	99.95	92.53	87.94	87.85	86.10	82.51
Days Payable Outstanding (DPO)	148.50	62.49	318.43	168.76	83.78	49.25	58.06	55.75	41.82	44.12	122.27
Cash Conversion Cycle (CCC)	174.38	135.72	147.21	98.47	202.56	129.93	107.06	103.32	113.99	112.56	33.59
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	269	269	239	241	245	240	243	242	223	232	130
Invested Capital Turnover	1.14	1.44	1.81	1.79	1.19	1.32	1.58	1.78	2.01	2.21	3.05
Increase / (Decrease) in Invested Capital	285	278	230	186	-24	-28	4.16	1.41	-23	-8.88	-112
Enterprise Value (EV)	1,210	1,396	1,185	1,623	1,874	2,000	2,218	2,508	3,614	3,976	5,462
Market Capitalization	1,210	1,376	1,181	1,611	1,861	1,985	2,208	2,521	3,683	4,060	5,574
Book Value per Share	$7.03	$5.33	$4.99	$4.86	$4.86	$4.70	$4.76	$5.15	$5.81	$6.12	$4.02
Tangible Book Value per Share	$0.28	($0.09)	($0.49)	($0.70)	($0.50)	($0.50)	($0.22)	$0.35	$1.20	$1.05	($0.19)
Total Capital	575	555	541	536	540	534	542	564	601	624	553
Total Debt	306	306	307	307	308	308	309	309	309	310	310
Total Long-Term Debt	306	306	307	307	308	308	309	309	309	310	310
Net Debt	-0.01	20	3.99	12	13	15	9.50	-13	-69	-83	-112
Capital Expenditures (CapEx)	0.00	0.00	0.01	0.78	0.18	0.02	0.04	0.13	0.19	0.60	0.66
Debt-free, Cash-free Net Working Capital (DFCFNWC)	7.89	14	-19	-23	-14	-15	5.14	3.57	-5.81	-41	-91
Debt-free Net Working Capital (DFNWC)	314	300	284	256	271	266	283	309	370	344	297
Net Working Capital (NWC)	314	300	284	256	271	266	283	309	370	344	297
Net Nonoperating Expense (NNE)	5.98	13	6.75	7.68	5.36	6.83	4.05	2.37	-0.04	2.53	238
Net Nonoperating Obligations (NNO)	-0.01	20	3.99	12	13	15	9.50	-13	-69	-83	-112
Total Depreciation and Amortization (D&A)	3.07	5.89	6.08	6.26	6.48	6.47	6.49	6.48	6.51	6.51	7.33
Debt-free, Cash-free Net Working Capital to Revenue	5.45%	7.59%	-8.61%	-8.74%	-4.56%	-4.31%	1.36%	0.83%	-1.23%	-7.85%	-16.04%
Debt-free Net Working Capital to Revenue	216.90%	161.22%	126.59%	96.65%	88.22%	79.03%	74.68%	71.91%	78.47%	65.97%	52.07%
Net Working Capital to Revenue	216.90%	161.22%	126.59%	96.65%	88.22%	79.03%	74.68%	71.91%	78.47%	65.97%	52.07%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.57)	($0.69)	($0.54)	($0.52)	($0.30)	($0.49)	($0.30)	($0.12)	$0.06	($0.11)	($13.43)
Adjusted Weighted Average Basic Shares Outstanding	41.10M	40.89M	46.93M	47.24M	47.78M	47.52M	48.89M	49.73M	50.64M	50.20M	58.85M
Adjusted Diluted Earnings per Share	($0.57)	($0.69)	($0.54)	($0.52)	($0.30)	($0.49)	($0.30)	($0.12)	$0.05	($0.10)	($13.43)
Adjusted Weighted Average Diluted Shares Outstanding	41.10M	40.89M	46.93M	47.24M	47.78M	47.52M	48.89M	49.73M	56.99M	50.20M	58.85M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	46.61M	47.00M	47.13M	47.71M	48.00M	49.01M	49.53M	50.24M	51.39M	60.34M	60.98M
Normalized Net Operating Profit after Tax (NOPAT)	-18	-23	-19	-17	-8.88	-17	-11	-3.49	1.82	-3.20	-553
Normalized NOPAT Margin	-36.89%	-32.79%	-26.77%	-21.78%	-9.82%	-17.06%	-9.52%	-2.73%	1.37%	-2.15%	-345.65%
Pre Tax Income Margin	-48.90%	-50.94%	-35.62%	-30.82%	-15.37%	-24.51%	-12.23%	-4.27%	1.99%	-3.33%	-493.91%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-6.67	-10.00	-6.91	-6.70	-3.84	-6.70	-3.64	-1.37	0.83	-1.33	-218.33
NOPAT to Interest Expense	-4.93	-6.40	-5.18	-4.75	-2.48	-4.74	-2.96	-0.97	0.79	-0.89	-152.83
EBIT Less CapEx to Interest Expense	-6.67	-10.00	-6.91	-6.92	-3.89	-6.71	-3.65	-1.40	0.78	-1.50	-218.51
NOPAT Less CapEx to Interest Expense	-4.93	-6.40	-5.18	-4.97	-2.53	-4.74	-2.97	-1.01	0.74	-1.06	-153.01
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-0.17%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Here’s a concise four-year view of Mirum Pharmaceuticals (NASDAQ:MIRM) using the quarterly data provided through Q4 2025. The highlights show accelerating revenue in 2025, a path toward profitability in mid-2025, and meaningful cash liquidity, alongside ongoing expense pressure and a sizable debt load.

Revenue momentum: Mirum’s quarterly revenue climbs over the period, culminating in 148.9 million in Q4 2025 (vs 99.4 million in Q4 2024 and 69.6 million in Q4 2023), pointing to a strengthening topline.
Strong gross margins: Gross profit in Q4 2025 is 120.7 million on 148.9 million in revenue, a gross margin near 81%, continuing the high-margin profile seen in 2023–2024 quarters.
Turning toward profitability in 2025: Net income swung to a positive 2.9 million in Q3 2025 (EPS +0.06), indicating an improving profitability trajectory before a small Q4 2025 loss; this contrasts with multi-quarter net losses earlier in 2022–2024.
Improving operating cash flow: Net cash from continuing operating activities was about 39.7 million in Q3 2025 and remained positive in Q4 2025 (around 6.1 million), signaling better cash-generation ability from core operations.
Capital-raising activity supports liquidity: Mirum continued to raise cash via equity issuances in 2025 (e.g., Q3 2025 issuance ~16.1 million, Q4 2025 ~9.0 million; earlier quarters also saw equity raises), providing liquidity to fund growth while reducing near-term liquidity concerns.
Strong balance-sheet liquidity trend: Total assets rose to approximately 785 million by Q3 2025, with cash balances around 282 million at that time, suggesting improved liquidity position versus earlier periods.
Ongoing investment in intangibles and R&D: Intangible assets are sizable (roughly 230–260 million across 2023–2025 quarters), and R&D expenses remain a meaningful portion of operating costs (roughly 42–46 million per quarter in 2025), reflecting continued investment in pipeline and development.
Expense backbone: Selling, general & administrative (SG&A) and R&D continue to represent substantial ongoing costs (e.g., combined 100–125 million of operating expenses in several 2024–2025 quarters), a typical profile for a growing biotech near commercialization or scale-up phase.
Leverage and debt: Long-term debt sits in the low-to-mid 300 million range by 2025, with interest expense in the single-digit millions quarterly, a factor for leverage and future financing considerations.
Net income remains volatile and often negative: Despite a positive quarterly print in Q3 2025, Mirum posted a net loss again in Q4 2025 (-5.7 million) and has reported substantial net losses in several earlier quarters, reflecting ongoing profitability challenges.
Persistent accumulated deficits on retained earnings: Retained earnings are negative across the period, contributing to negative total equity pressure and highlighting the need for sustained earnings or strategic financing to de-risk the balance sheet.

05/14/26 05:21 AM ETAI Generated. May Contain Errors.

Mirum Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Mirum Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

In the past 6 years, Mirum Pharmaceuticals' net income has ranged from -$163.42 million in 2023 to -$23.36 million in 2025, and is currently -$23.36 million as of their latest financial filing in 2025. See where experts think Mirum Pharmaceuticals is headed by visiting Mirum Pharmaceuticals' forecast page.

Mirum Pharmaceuticals' total operating income in 2025 was -$22.14 million, based on the following breakdown:

Total Gross Profit: $421.07 million
Total Operating Expenses: $443.21 million

Over the last 6 years, Mirum Pharmaceuticals' total revenue changed from $0.00 in 2019 to $521.31 million in 2025, a change of 52,131,200,000.0%.

Mirum Pharmaceuticals' total liabilities were at $528.12 million at the end of 2025, a 18.6% increase from 2024, and a 21,464.8% increase since 2018.

In the past 7 years, Mirum Pharmaceuticals' cash and equivalents has ranged from $11.97 million in 2019 to $296.68 million in 2025, and is currently $296.68 million as of their latest financial filing in 2025.

Over the last 6 years, Mirum Pharmaceuticals' book value per share changed from 5.67 in 2019 to 6.12 in 2025, a change of 8.0%.

Related Companies

Financial statements for NASDAQ:MIRM last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mirum Pharmaceuticals (MIRM) Financials

Financials Breakdown Chart

Key Financial Trends

Mirum Pharmaceuticals Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mirum Pharmaceuticals (MIRM) Financials

Annual Income Statements for Mirum Pharmaceuticals

Quarterly Income Statements for Mirum Pharmaceuticals

Annual Cash Flow Statements for Mirum Pharmaceuticals

Quarterly Cash Flow Statements for Mirum Pharmaceuticals

Annual Balance Sheets for Mirum Pharmaceuticals

Quarterly Balance Sheets for Mirum Pharmaceuticals

Annual Metrics And Ratios for Mirum Pharmaceuticals

Quarterly Metrics And Ratios for Mirum Pharmaceuticals

Financials Breakdown Chart

Key Financial Trends

Mirum Pharmaceuticals Financials - Frequently Asked Questions

When does Mirum Pharmaceuticals' financial year end?

How has Mirum Pharmaceuticals' net income changed over the last 6 years?

What is Mirum Pharmaceuticals' operating income?

How has Mirum Pharmaceuticals' revenue changed over the last 6 years?

How much debt does Mirum Pharmaceuticals have?

How much cash does Mirum Pharmaceuticals have?

How has Mirum Pharmaceuticals' book value per share changed over the last 6 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools